A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Khasraw, M; McDonald, KL; Rosenthal, M; Lwin, Z; Ashley, DM; Wheeler, H; Barnes, E; Koh, E-S; Foote, MC; Buckland, M; Fisher, L; Leonard, R; Hall, M; Yip, S; Simes, J

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 2045 - 2045

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.2045